Local view for "http://purl.org/linkedpolitics/eu/plenary/2014-04-03-Speech-4-223-035"
| Predicate | Value (sorted: default) |
|---|---|
| rdf:type | |
| dcterms:Date | |
| dcterms:Is Part Of | |
| dcterms:Language | |
| lpv:document identification number |
"en.20140403.89.4-223-035"2
|
| lpv:hasSubsequent | |
| lpv:speaker | |
| lpv:spoken text |
"I welcome the focus of this Report toward setting guidelines for safe and effective clinical trials of medicinal products. Investing in our health research infrastructure is crucial to ensuring that the quality of patient services, and processes used to prevent, diagnose and treat disease, continues to improve in a medical environment with many challenges. In my own constituency, Northern Ireland, a new medical research centre in Belfast worth GBP 4 million was opened in September 2013. It is part of a joint venture between academic institutions, the Belfast Health and Social Care Trust and Public Health Agency. This resource will be key to gaining new knowledge which can then be applied and put into practice with great benefits for people across the Province.
The Committee’s Report would strengthen the principle of informed consent for clinical trials. It would also ensure research proposals are effectively assessed, and that they compel better disclosure of trial results – negative or positive. Trials which may result in inheritable changes to a person would be banned. This transparency and foresight in relation to the preparation of, and consequences stemming from, clinical trials is vital to ensure safety and good practice. I therefore welcome the proposals."@en1
|
| lpv:spokenAs | |
| lpv:unclassifiedMetadata |
Named graphs describing this resource:
The resource appears as object in 2 triples